194 related articles for article (PubMed ID: 38050190)
1. Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.
Wu G; Wang Q; Wang D; Xiong F; Liu W; Chen J; Wang B; Huang W; Wang X; Chen Y
Clin Transl Med; 2023 Dec; 13(12):e1502. PubMed ID: 38050190
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
3. EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes.
Zhang J; Chen W; Ma W; Han C; Song K; Kwon H; Wu T
Am J Pathol; 2022 Dec; 192(12):1712-1724. PubMed ID: 36456043
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic network of EZH2/SFRP1/Wnt in the epithelial-mesenchymal transition of laryngeal carcinoma cells.
Chen W; Wang HT; Ji JF; Wang ZY; Shi T; Wu MH; Yu PJ
Neoplasma; 2022 May; 69(3):680-690. PubMed ID: 35400167
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression.
Yu Y; Chen Q; Zhang X; Yang J; Lin K; Ji C; Xu A; Yang L; Miao L
Cancer Sci; 2020 Jul; 111(7):2297-2309. PubMed ID: 32378752
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
8. Silencing of MBD2 and EZH2 inhibits the proliferation of colorectal carcinoma cells by rescuing the expression of SFRP.
Xie Y; Wang F; Yu J; Zhang J; Liu Y; Li M; Qi J
Oncol Rep; 2021 Dec; 46(6):. PubMed ID: 34617573
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
10. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
11. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis.
Ma J; Weng L; Wang Z; Jia Y; Liu B; Wu S; Cao Y; Sun X; Yin X; Shang M; Mao A
Exp Cell Res; 2018 May; 366(2):103-113. PubMed ID: 29530475
[TBL] [Abstract][Full Text] [Related]
12. MBD2 and EZH2 regulate the expression of SFRP1 without affecting its methylation status in a colorectal cancer cell line.
Yu J; Xie Y; Liu Y; Wang F; Li M; Qi J
Exp Ther Med; 2020 Dec; 20(6):242. PubMed ID: 33178340
[TBL] [Abstract][Full Text] [Related]
13. Dicer promotes tumorigenesis by translocating to nucleus to promote SFRP1 promoter methylation in cholangiocarcinoma cells.
Cheng W; Qi Y; Tian L; Wang B; Huang W; Chen Y
Cell Death Dis; 2017 Feb; 8(2):e2628. PubMed ID: 28230864
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of RSPO3 via targeted promoter DNA demethylation inhibits the progression of cholangiocarcinoma.
Wu G; Wang D; Xiong F; Liu W; Wang Q; Chen J; Wang B; Chen Y
Clin Epigenetics; 2023 Nov; 15(1):177. PubMed ID: 37932819
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma.
Yu Y; Zhang M; Wang N; Li Q; Yang J; Yan S; He X; Ji G; Miao L
Cell Death Dis; 2018 Jul; 9(7):746. PubMed ID: 29970899
[TBL] [Abstract][Full Text] [Related]
16. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma.
Xu Y; Yao Y; Jiang X; Zhong X; Wang Z; Li C; Kang P; Leng K; Ji D; Li Z; Huang L; Qin W; Cui Y
J Exp Clin Cancer Res; 2018 Apr; 37(1):81. PubMed ID: 29642935
[TBL] [Abstract][Full Text] [Related]
17. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation.
Rush M; Appanah R; Lee S; Lam LL; Goyal P; Lorincz MC
Epigenetics; 2009 Aug; 4(6):404-14. PubMed ID: 19717977
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
19. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
[No Abstract] [Full Text] [Related]
20. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
